Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)

NCT01212094 is registered in ClinicalTrials.gov with National Institute of Neurological Disorders and Stroke (NINDS) as lead sponsor.

NCT NCT01212094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01212094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind Combination of Rituximab by Intravenous and Intrathecal Injection Versus Placebo in Patients With Low-Inflammatory Secondary Progressive Multiple Sclerosis (RIVITaLISe)
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
Phase
Phase 1/2
Overall status
Terminated
Start date
September 30, 2010
Completion date
December 31, 2015
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis